Norwegian version of this page

HAB - Evaluation of heroin-assisted treatment

This project aims to evaluate how patients respond to heroin-assisted treatment.

About the project

Opioid use disorder (OUD) can be a chronic condition that leads to increased morbidity and mortality. OUD is often treated with medication-assisted rehabilitation (MAR). For some, the usual medications used in MAR have not been sufficiently effective. Heroin-assisted treatment (HAT) is a new treatment approach in Norway and involves the prescription of pharmaceutical heroin (diacetylmorphine) administered in a supervised setting.

In 2020, the government introduced a 5-year pilot project with HAT in Oslo and Bergen to reach those with severe OUD, where regular MAR has not provided a sufficient treatment effect.

Our research group consists of experienced national and international researchers who are evaluating the HAT pilot project through a coordinated and interdisciplinary approach, including the involvement of clinicians and user organizations.

Heroin-assisted treatment in Oslo (HABiO) began in January 2022. You can find out more about HABiO (in Norwegian).

Heroin-assisted treatment in Bergen (HABiB) began in March 2022. You can find more information about HABiB (in Norwegian).

Objectives

The overarching goal of this evaluation project is to investigate how patients respond to HAT and gain a better understanding of how the treatment works over time.

By using different research methods, including questionnaires and national registry data in addition to qualitative interviews, this project will evaluate HAT based on several criteria. The project aims to:

  • explore attitudes and experiences with HAT among patients, relatives and healthcare professionals;
  • describe changes in mental health, physical health and quality of life of HAT patients throughout the treatment;
  • report any serious side effects and events related to HAT, and conduct a cost-benefit analysis of the program; and
  • conduct a process and outcome assessment of the implementation of HAT. 

The project is expected to provide a knowledge base for deciding whether to continue with HAT after the trial period and potentially how HAT can be integrated into the Norwegian MAR system in the future.

The results of the research project will include an evaluation report to the Health Directorate, which will include a recommendation for potential continuation of HAT, as well as scientific articles.

Financing

  • Norwegian Directorate of Health
  • Stiftelsen Dam

Cooperation

  • Bergen Addiction Research, Helse Bergen Haukeland University Hospital
  • Centre for Alcohol and Drug Research, Aarhus University, Denmark
  • proLAR Nett
  • Section for Clinical Addiction Research (RusForsk), Oslo University Hospital
     

Selected publications

Published Mar. 23, 2021 5:27 PM - Last modified Feb. 6, 2024 10:43 AM

Contact

Project Leader

Participants

Detailed list of participants